Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease — NEPHRO-DREPA  

Anemia Clinical Trial

Official title: Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease

Status Recruiting

Clinical Trial Summary

Sickle cell disease is the subject of targeted neonatal screening (carried out when one of the two parents is from an endemic country - sub-Saharan Africa, South-East Asia, Central America, the Caribbean) during the Guthrie test. Haemolysis, which results from the abnormality of the haemoglobin, and the vascular activation it causes, are responsible for multiple organ damage. Major sickle cell syndromes (MSC), by several mechanisms, are responsible for a wide range of renal damage, culminating in end-stage renal failure at an average age of 45 years and with an average survival of 3 years beyond ESRD.

The various renal disorders are : glomerular hyperfiltration and then glomerulosclerosis; tubular dysfunction, especially proximal and distal hyposthenuria (a factor in enuresis); papillary necrosis, renal infarction, episodes of acute renal failure during vaso-occlusive crises; dysregulation of the renin-angiotensin system with early arterial hypertension and, more rarely, extra-membranous glomerulonephritis. In the early stages of these conditions, simple paraclinical tests can identify them before the appearance of specific clinical signs.

In patients suffering from MDS, the HAS (High Authority of Health) recommends an annual check-up carried out in a Competence Centre. According to the HAS recommendations for annual surveillance, in addition to the search for other organic complications, for renal pathology, only microalbuminuria and renal ultrasound are recommended. However, as the literature shows, microalbuminuria and ultrasound only detect some of these renal disorders and at a very late stage. A large number of publications in adults and, to a lesser degree, in children, demonstrate the correlation between the frequency of acute complications of sickle cell disease (episodes of haemolysis, etc.) and the occurrence of kidney damage.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Sickle Cell Disease

• NCT number: NCT05211037
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Camille FAUDEUX, Dr
• Phone: 4.92.03.63.65
• Email: faudeux.c@chu-nice.fr
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2022
• Completion date: September 2024